

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method for diagnosis of a disorder associated with the development of beta amyloid deposits or fibrils in a human or animal subject or assessing the efficacy of treatment rendered to the subject for such disorder, said method comprising the step of:
 - A) determining the presence of mtDNA CR mutations.
2. (Original) A method according to Claim 1, wherein Step A comprises making a qualitative determination that mtDNS CR mutation is or is not present.
3. (Original) A method according to Claim 1, wherein Step A comprises making a quantitative determination of mtDNS CR mutations.
4. (Original) A method according to Claim 3 further comprising the step of:
 - B) comparing a mtDNS CR value obtained by the quantitative determination made in Step A with a control mtDNS CR value to determine whether the subject has significantly more mtDNS CR mutations than control.
5. (Original) A method according to Claim 3 further comprising the step of:
 - B) comparing a mtDNS CR value obtained by the quantitative determination made in Step A with a mtDNS CR value representative of subjects who suffer from a disorder associated with the development of beta amyloid deposits or fibrils.

6. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T4141G mutation.

7. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T414C mutation.

8. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T477C mutation.

9. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T146C mutation.

10. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T152C mutation.

11. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a A189G mutation.

12. (Original) A method according to any of Claim 1 wherein Step A comprises testing for a T195C mutation.

13. (Original) A method according to Claim 1 wherein Step A is carried out at least in part by PNA-clamping PCR.

14. (Original) A method according to Claim 1 wherein Step A is carried out at least in part by oligonucleotide hybridization.

15. (Original) A method according to Claim 1 wherein Step A is carried out at least in part by primer extension.

16. (Original) A method according to Claim 1 wherein Step A is carried out at least in part by restriction digestion.

17. (Original) A method according to Claim 1 wherein the determination of Step A is made in a specimen of tissue, cells or body fluid selected from the group consisting of:

- i. brain tissue;
- ii. brain tissue from the frontal cortex;
- iii. nervous tissue;
- iv. nerve cells
- v. blood
- vi. blood cells;
- vii. urine;
- viii. urinary tract cells;
- ix. skin;
- x. skin cells;
- xi. epithelium;
- xii. epithelial cells;
- xiii. fibroblasts;
- xiv. cerebrospinal fluid; and
- xv. cells contained in cerebrospinal fluid.

18. (Original) A method according to Claim 1 wherein the method is carried out for post-symptomatic diagnosis of a disorder in a subject who has begun to exhibit symptoms of that disorder.

19. (Original) A method according to Claim 1 wherein the method is carried out for pre-symptomatic diagnosis of a disorder in a subject who has not begun to exhibit symptoms of that disorder.

20. (Original) A method according to Claim 1 wherein the disorder is a neurodegenerative disease.
21. (Original) A method according to Claim 1 wherein the disorder is Alzheimer's Disease.
22. (Original) A method according to Claim 1 wherein the disorder is Parkinson's Disease.
23. (Original) A method according to Claim 1 wherein the disorder is Down's Syndrome-associated dementia.
24. (Original) A method according to Claim 1 wherein the disorder is a spongiform encephalopathy.
25. (Original) A method according to Claim 1 wherein the disorder is type II diabetes .
26. (Original) A method according to Claim 1 wherein the disorder is Creutzfeldt-Jakob disease.
27. (Original) A method according to Claim 1 wherein the disorder is a Huntington's disease.
28. (Original) A method according to Claim 1 wherein the disorder is macular degeneration.
29. (Original) A method according to Claim 1 wherein the disorder is a prion disease.
30. (Original) A method according to Claim 1 wherein Step A comprises:
obtaining sample cells from the subject;
extracting DNA from the sample cells;
subjecting the extracted DNA to mitochondrial DNA control region amplification;
determining whether homoplasmic 414 and 477 nucleotide variants are present by direct sequencing for heteroplasmic 414 and 477 nucleotide mutations; and

if 414 and 477 nucleotide variants are detected, cloning the mutant molecules and sequencing the clone.

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)